OBJECTIVE: The Pipeline embolization device (PED; Chestnut Medical, Menlo Park, CA) is a new endovascular construct designed to exclude aneurysms from the parent cerebrovasculature. We report the results of the first two human implantations of this device in North America. CLINICAL PRESENTATION: Two patients presenting with large, symptomatic, circumferential, fusiform intracranial vertebral artery aneurysms were treated with the PED. In both cases, more traditional open microneurosurgical and neuroendovascular treatment strategies had either failed or were associated with unacceptably high risk. INTERVENTION: Three PEDs were placed across the aneurysms in each of the patients to achieve reconstruction of a new parent vessel through the center of a circumferential aneurysm. In the first patient, who had previously been treated with stent-supported coil embolization, the PED construct alone was sufficient to achieve parent vessel reconstruction and exclusion of the recurrent aneurysm. In the second patient, a microcatheter was jailed within the saccular portion of the aneurysm and the parent vessel was reconstructed with three telescoped PEDs. Although the PED construct dramatically reduced flow into the aneurysm, the lesion remained patent. Coiling of the saccular portion of the aneurysm was subsequently performed via the jailed microcatheter. Follow-up angiography performed 72 hours after the procedure demonstrated occlusion of the aneurysm with cylindrical reconstruction of the affected vascular segment. Neither patient has experienced any complication in the periprocedural period (30 d) or during subsequent long-term (>1 year) follow-up. CONCLUSION: The PED represents an important advance in the endovascular therapy of cerebral aneurysms, targeting primary parent vessel reconstruction rather than endosaccular occlusion as a means by which to achieve exclusion of the aneurysm and definitive anatomic reconstruction of the parent artery.
OBJECTIVE: The Pipeline embolization device (PED; Chestnut Medical, Menlo Park, CA) is a new endovascular construct designed to exclude aneurysms from the parent cerebrovasculature. We report the results of the first two human implantations of this device in North America. CLINICAL PRESENTATION: Two patients presenting with large, symptomatic, circumferential, fusiform intracranial vertebral artery aneurysms were treated with the PED. In both cases, more traditional open microneurosurgical and neuroendovascular treatment strategies had either failed or were associated with unacceptably high risk. INTERVENTION: Three PEDs were placed across the aneurysms in each of the patients to achieve reconstruction of a new parent vessel through the center of a circumferential aneurysm. In the first patient, who had previously been treated with stent-supported coil embolization, the PED construct alone was sufficient to achieve parent vessel reconstruction and exclusion of the recurrent aneurysm. In the second patient, a microcatheter was jailed within the saccular portion of the aneurysm and the parent vessel was reconstructed with three telescoped PEDs. Although the PED construct dramatically reduced flow into the aneurysm, the lesion remained patent. Coiling of the saccular portion of the aneurysm was subsequently performed via the jailed microcatheter. Follow-up angiography performed 72 hours after the procedure demonstrated occlusion of the aneurysm with cylindrical reconstruction of the affected vascular segment. Neither patient has experienced any complication in the periprocedural period (30 d) or during subsequent long-term (>1 year) follow-up. CONCLUSION: The PED represents an important advance in the endovascular therapy of cerebral aneurysms, targeting primary parent vessel reconstruction rather than endosaccular occlusion as a means by which to achieve exclusion of the aneurysm and definitive anatomic reconstruction of the parent artery.
Authors: J P Cruz; M Chow; C O'Kelly; B Marotta; J Spears; W Montanera; D Fiorella; T Marotta Journal: AJNR Am J Neuroradiol Date: 2012-03-08 Impact factor: 3.825
Authors: Z Kulcsár; E Houdart; A Bonafé; G Parker; J Millar; A J P Goddard; S Renowden; G Gál; B Turowski; K Mitchell; F Gray; M Rodriguez; R van den Berg; A Gruber; H Desal; I Wanke; D A Rüfenacht Journal: AJNR Am J Neuroradiol Date: 2010-11-11 Impact factor: 3.825
Authors: M Leonardi; L Cirillo; F Toni; M Dall'olio; C Princiotta; A Stafa; L Simonetti; R Agati Journal: Interv Neuroradiol Date: 2011-10-17 Impact factor: 1.610